Abstract | PURPOSE: EXPERIMENTAL DESIGN: RESULTS:
90Y-CHX-A''-DTPA-hu3S193 retained excellent immunoreactivity after radiolabeling. The biodistribution study showed excellent uptake in tumor (90.33 +/- 38.84%ID/g) peaking at 24 to 72 hours after injection and with prolonged retention. 90Y-CHX-A''-DTPA-hu3S193 significantly inhibited A431 xenograft growth at 25, 50, and 100 microCi doses. The combination of 0.4 mg AG1478 with a single dose of 25 microCi 90Y-CHX-A''-DTPA-hu3S193 resulted in a significant enhancement of efficacy compared with either agent alone (P = 0.013). CONCLUSIONS:
|
Authors | Fook T Lee, Angela J Mountain, Marcus P Kelly, Cathrine Hall, Angela Rigopoulos, Terrance G Johns, Fiona E Smyth, Martin W Brechbiel, Edouard C Nice, Antony W Burgess, Andrew M Scott |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 11
Issue 19 Pt 2
Pg. 7080s-7086s
(Oct 01 2005)
ISSN: 1078-0432 [Print] United States |
PMID | 16203806
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 90Y-CHX-A''-DTPA-hu3S193
- Antibodies, Monoclonal
- Antineoplastic Agents
- Enzyme Inhibitors
- Lewis Blood Group Antigens
- Lewis Y antigen
- Quinazolines
- Radiopharmaceuticals
- Tyrphostins
- Yttrium Radioisotopes
- RTKI cpd
- Pentetic Acid
- ErbB Receptors
- Protein-Tyrosine Kinases
|
Topics |
- Animals
- Antibodies, Monoclonal
(chemistry, pharmacology)
- Antineoplastic Agents
(pharmacology)
- Cell Line, Tumor
- Enzyme Inhibitors
(pharmacology)
- ErbB Receptors
(antagonists & inhibitors)
- Female
- Humans
- Lewis Blood Group Antigens
(immunology)
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neoplasm Transplantation
- Pentetic Acid
(chemistry, pharmacology)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Quinazolines
- Radioimmunotherapy
(methods)
- Radiopharmaceuticals
(therapeutic use)
- Signal Transduction
- Time Factors
- Tissue Distribution
- Tyrphostins
(pharmacology)
- Yttrium Radioisotopes
(therapeutic use)
|